McDonald, A. B. Et Al. 2023. Efficacy and safety of pembrolizumab every six weeks in relapsed/refractory classical Hodgkin lymphoma or primary mediastinal B-cell lymphoma: The phase 2 KEYNOTE-B68 trial.. JOURNAL OF CLINICAL ONCOLOGY , vol.41, no.16 .

McDonald, A. B., Verburgh, E., Gotti, M., Pinto, A., Zaucha, J., Ivanov, V., ... Melnichenko, V.(2023). Efficacy and safety of pembrolizumab every six weeks in relapsed/refractory classical Hodgkin lymphoma or primary mediastinal B-cell lymphoma: The phase 2 KEYNOTE-B68 trial.. JOURNAL OF CLINICAL ONCOLOGY , vol.41, no.16.

McDonald, Andrew Et Al. "Efficacy and safety of pembrolizumab every six weeks in relapsed/refractory classical Hodgkin lymphoma or primary mediastinal B-cell lymphoma: The phase 2 KEYNOTE-B68 trial.," JOURNAL OF CLINICAL ONCOLOGY , vol.41, no.16, 2023

McDonald, Andrew B. Et Al. "Efficacy and safety of pembrolizumab every six weeks in relapsed/refractory classical Hodgkin lymphoma or primary mediastinal B-cell lymphoma: The phase 2 KEYNOTE-B68 trial.." JOURNAL OF CLINICAL ONCOLOGY , vol.41, no.16, 2023

McDonald, A. B. Et Al. (2023) . "Efficacy and safety of pembrolizumab every six weeks in relapsed/refractory classical Hodgkin lymphoma or primary mediastinal B-cell lymphoma: The phase 2 KEYNOTE-B68 trial.." JOURNAL OF CLINICAL ONCOLOGY , vol.41, no.16.

@article{article, author={Andrew Bruce McDonald Et Al. }, title={Efficacy and safety of pembrolizumab every six weeks in relapsed/refractory classical Hodgkin lymphoma or primary mediastinal B-cell lymphoma: The phase 2 KEYNOTE-B68 trial.}, journal={JOURNAL OF CLINICAL ONCOLOGY}, year=2023}